New Report Covers Gastrin/Cholecystokinin Type B Receptor - Pipeline Review, H1 2016

Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) - Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) targeted pipeline therapeutics.

The report provides comprehensive information on the Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) targeted therapeutics development and features dormant and discontinued projects.

To access full report with TOC, please visit Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) - Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report reviews Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) targeted therapeutics

Reasons to buy

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Companies Mentioned

Johnson & Johnson Zealand Pharma A/S Zeria Pharmaceutical Co., Ltd.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###